Abstract
The article presents the data about the new molecule inhaled glucocrticosteroid (iGCS) - ciclesonide in a new delivery device pMDA-HFA. A detailed analysis of the main characteristics of the drug molecules and means of their delivery was conducted according to international data. The results of observational study of the use of Alvesco in bronchial asthma patients in the real clinical practice of the Institute of Immunology are discussed.
Reference32 articles.
1. Everard M.L., Devadason S.G., Le Souëf PN. Flow early in the inspiratory manoeuvre affects the aerosol particle size distribution from a Turbuhaler. Respir. Med. 1997, v. 91, р. 624-628.
2. Nave R., Mueller H. From inhaler to lung: clinical implications of the formulations of ciclesonide and other inhaled corticosteroids. Int. J. Gen. Med. 2013, v. 6, р. 99-107.
3. Williams L.K., Pladevall M., Xi H. et al. Relationship between adherence to inhaled corticosteroids and poor outcomes among adults with asthma. J. Allergy Clin. Immunol. 2004, v. 114, р. 1288-1293.
4. Leach C., Colice G.L., Luskin A. Particle size of inhaled corticosteroids: does it matter? J. Allergy Clin. Immunol. 2009, v. 124, р. 88-93.
5. Dolovich M.A. Influence of inspiratory flow rate, particle size, and airway caliber on aerosolized drug delivery to the lung. Respir. Care. 2000, v. 45, р. 597-608.